CPS
  • Home

Sign in or register to track your progress, save, and view your completed history.

Breast Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head & Neck Cancer, Lung Cancer, Urothelial Cancer

Podcast Episode 2: Resection to Report - The PD-L1 Testing Journey

    clockimg 36m
  • Podcast
  • Foundational
 saveimgSave unsaveimgUnsave

The second episode of the "Dialogues in CDx" podcast series takes a closer look at the PD-L1 testing journey. Using England as example, you’ll learn about the process from start to finish, the importance of turnaround times, reflex testing, optimal oncologist-pathologist collaboration, and more.  

 

Joining this discussion are two esteemed guests, providing perspectives from both a pathologist’s and an oncologist’s viewpoint.

 

Dr. Phillipe Taniere is a Consultant Histopathologist and Clinical Service Lead for Molecular Pathology at University Hospitals Birmingham. Dr. Tanière’s department completed 20,000 CDx tests last year and is therefore an ideal candidate for this discussion.  

 

Also joining is Dr. Shobhit Baijal, a Consultant Medical Oncologist at the University Hospitals Birmingham NHS Trust and an Honorary Associate Professor at the University of Birmingham where he specializes in the treatment of thoracic and colorectal malignancies. Dr. Baijal specializes in all forms of cancer therapy and is a UK Chief and Principal Investigator for National and International studies. He is also a steering committee member of the British Thoracic Oncology Group. His vast experience provides invaluable input to the discussion.   
 

The topics covered in this conversation include: 

  • The clinical significance of PD-L1 and the needs of the oncologist
  • The PD-L1 testing journey as seen by the oncologist and the pathologist 
  • Typical turnaround times (TAT) and their dependencies 
  • The case of England: Who performs PD-L1 testing and its impact on the oncologist 
  • PD-L1 reporting: The oncologist-pathologist connection 

 

Dr. Philippe Taniere

Pathologist Consultant​​, University Hospital Birmingham​

Dr. Shobhit Baijal

Consultant Medical Oncologist, University Hospitals Birmingham NHS Trust

Scott Boyer, PhD, MBA

Global Product Manager, Agilent Technologies​

Related Training

The views and opinions expressed by the guests on this podcast are their own and do not necessarily reflect the views or opinions of the host or of Agilent.

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.D0130686_1.00